211 related articles for article (PubMed ID: 17565640)
1. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis.
Ibañez P; Solis N; Pizarro M; Aguayo G; Duarte I; Miquel JF; Accatino L; Arrese M
J Gastroenterol Hepatol; 2007 Jun; 22(6):846-51. PubMed ID: 17565640
[TBL] [Abstract][Full Text] [Related]
2. Pentoxifylline does not prevent neither liver damage nor early profibrogenic events in a rat model of non-alcoholic steatohepatitis.
Vial P; Riquelme A; Pizarro M; Solís N; Madariaga JA; Aguayo G; Duarte I; Soza A; Accatino L; Arrese M
Ann Hepatol; 2006; 5(1):25-9. PubMed ID: 16531961
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II type 1 receptor antagonist improves the prognosis in rats displaying liver cirrhosis induced by a choline-deficient diet.
Iwata K; Sohda T; Irie M; Takeyama Y; Anan A; Shakado S; Sakisaka S
J Gastrointestin Liver Dis; 2008 Mar; 17(1):21-5. PubMed ID: 18392239
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the renin-angiotensin system attenuates the development of liver fibrosis and oxidative stress in rats.
El-Demerdash E; Salam OM; El-Batran SA; Abdallah HM; Shaffie NM
Clin Exp Pharmacol Physiol; 2008 Feb; 35(2):159-67. PubMed ID: 17900296
[TBL] [Abstract][Full Text] [Related]
5. Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator-activated receptor alpha ligand in rats.
Rao MS; Papreddy K; Musunuri S; Okonkwo A
In Vivo; 2002; 16(2):145-52. PubMed ID: 12073774
[TBL] [Abstract][Full Text] [Related]
6. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S
Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344
[TBL] [Abstract][Full Text] [Related]
7. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis.
Uno M; Kurita S; Misu H; Ando H; Ota T; Matsuzawa-Nagata N; Kita Y; Nabemoto S; Akahori H; Zen Y; Nakanuma Y; Kaneko S; Takamura T
Hepatology; 2008 Jul; 48(1):109-18. PubMed ID: 18571789
[TBL] [Abstract][Full Text] [Related]
8. Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
Shirai Y; Yoshiji H; Noguchi R; Kaji K; Aihara Y; Douhara A; Moriya K; Namisaki T; Kawaratani H; Fukui H
J Gastroenterol Hepatol; 2013 Apr; 28(4):723-30. PubMed ID: 23301938
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
Nan YM; Fu N; Wu WJ; Liang BL; Wang RQ; Zhao SX; Zhao JM; Yu J
Scand J Gastroenterol; 2009; 44(3):358-65. PubMed ID: 18991162
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model.
Sahai A; Malladi P; Melin-Aldana H; Green RM; Whitington PF
Am J Physiol Gastrointest Liver Physiol; 2004 Jul; 287(1):G264-73. PubMed ID: 15044174
[TBL] [Abstract][Full Text] [Related]
11. Effects of RNA interference targeting transforming growth factor-beta 1 on immune hepatic fibrosis induced by Concanavalin A in mice.
Xu W; Wang LW; Shi JZ; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):300-8. PubMed ID: 19502172
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.
Yokohama S; Yoneda M; Haneda M; Okamoto S; Okada M; Aso K; Hasegawa T; Tokusashi Y; Miyokawa N; Nakamura K
Hepatology; 2004 Nov; 40(5):1222-5. PubMed ID: 15382153
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Kaji K; Yoshiji H; Kitade M; Ikenaka Y; Noguchi R; Shirai Y; Aihara Y; Namisaki T; Yoshii J; Yanase K; Tsujimoto T; Kawaratani H; Fukui H
Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1094-104. PubMed ID: 21372165
[TBL] [Abstract][Full Text] [Related]
14. The expression of AT1 receptor on hepatic stellate cells in rat fibrosis induced by CCl4.
Wei H; Lu H; Li D; Zhan Y; Wang Z; Huang X
Chin Med J (Engl); 2001 Jun; 114(6):583-7. PubMed ID: 11780431
[TBL] [Abstract][Full Text] [Related]
15. Losartan attenuates ventilator-induced lung injury.
Yao S; Feng D; Wu Q; Li K; Wang L
J Surg Res; 2008 Mar; 145(1):25-32. PubMed ID: 17688881
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet.
Kawaguchi K; Sakaida I; Tsuchiya M; Omori K; Takami T; Okita K
Biochem Biophys Res Commun; 2004 Feb; 315(1):187-95. PubMed ID: 15013444
[TBL] [Abstract][Full Text] [Related]
17. Losartan attenuates bleomycin-induced pulmonary fibrosis in rats.
Yao HW; Zhu JP; Zhao MH; Lu Y
Respiration; 2006; 73(2):236-42. PubMed ID: 16330873
[TBL] [Abstract][Full Text] [Related]
18. [Mechanism of hepatocyte regeneration inhibition in rats with liver fibrosis induced by lipogenic methionine-choline- deficient diet].
Mu YP; Xi XH; Chen XR
Zhonghua Yi Xue Za Zhi; 2009 Dec; 89(48):3430-6. PubMed ID: 20223120
[TBL] [Abstract][Full Text] [Related]
19. Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis.
Kitamura K; Tada S; Nakamoto N; Toda K; Horikawa H; Kurita S; Tsunematsu S; Kumagai N; Ishii H; Saito H; Hibi T
J Gastroenterol Hepatol; 2007 Nov; 22(11):2022-33. PubMed ID: 17914985
[TBL] [Abstract][Full Text] [Related]
20. [Effect of ACE-I and AT-1 receptor blocker on the progression of CCl(4)-inducing rat hepatic fibrogenesis].
Li X; Meng Y; Zhang ZS; Yang XS; Wu PS
Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(14):1241-5. PubMed ID: 12930639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
